IDEAYA Biosciences GAAP EPS of -$0.94 beats by $0.03, revenue of $10.88M beats by $4.93M
Source: SeekingAlpha
2026-02-17 06:24:42 ET
More on IDEAYA Biosciences
- IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- GSK ends collaboration with IDEAYA for two candidates
- Seeking Alpha’s Quant Rating on IDEAYA Biosciences
Read the full article on Seeking Alpha
For further details see:
IDEAYA Biosciences GAAP EPS of -$0.94 beats by $0.03, revenue of $10.88M beats by $4.93M
IDEAYA Biosciences Inc.
NASDAQ: IDYA
IDYA Trading
0.49% G/L:
$34.96 Last:
186,017 Volume:
$35.27 Open:
IDYA Latest News
March 09, 2026 06:00:00 am
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
February 25, 2026 06:00:00 am
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
February 23, 2026 06:00:00 am
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
IDYA Stock Data
$2,916,661,394
85,474,748
1.71%
105
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
